WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
World Federation of Hemophilia shared on LinkedIn:
”The WFH has released new evidence-based guidelines on AAV gene therapy for hemophilia, covering eligibility, center readiness, infusion safety, and long-term monitoring.
A major step forward for people with bleedingdisorders.
Find out more”
The World Federation of Hemophilia (WFH) has released a new evidence-based clinical practice guideline focused on adeno-associated virus (AAV) gene therapy for people with hemophilia (PwH).
This marks the addition of a dedicated gene therapy section within the broader WFH Guidelines for the Management of Hemophilia.
The guideline offers practical, up-to-date recommendations to support clinicians and patients in navigating this rapidly advancing treatment landscape.
It aims to promote safe, informed, and equitable use of gene therapy across the global bleeding disorders community.
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India
-
Oct 20, 2026, 03:31Zena Vexler: Targeting Neutrophil Elastase and NETosis to Mitigate Infection-Triggered Childhood Stroke
-
Oct 20, 2026, 03:24Chaza Alaji: Diagnosing Protein C and Protein S Deficiency
-
Oct 20, 2026, 03:24Mou Nandi: How Maternal Health During Pregnancy May Shape Infant Development
-
Oct 20, 2026, 03:13Sumyea Kabir: Pre-Analytical Quality in Phlebotomy – Preventing In Vitro Hemolysis